Cambrex Invests in Expansion at Swedish Facility
News Sep 09, 2016
Cambrex Corporation has announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden. The investment includes the installation of new multi-purpose reactors ranging from 4m3 to 12m3 and upgrading of the control room within an existing plant on site.
The new facilities will undergo validation and cGMP qualification ahead of the operational startup in Q4 2016. This extra capacity increases the large scale manufacturing capabilities of the Karlskoga facility, which supports clients’ development projects from R&D through to large scale commercial manufacturing.
“Our facility at Karlskoga is strategically important, both in Scandinavia and the wider European markets, and this investment is in response to an increase in demand for larger scale, multi-purpose manufacturing capabilities,” commented Bjarne Sandberg, Managing Director, Cambrex Karlskoga.
“By creating greater capacity within the current infrastructure, we have combined expansion and efficiency at the site, both of which will benefit our customers.” The expansion at Cambrex’s Swedish site is part of an ongoing strategic campaign to invest in small molecule API manufacturing across its global network of facilities.
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
New Research Hub to Tackle Global Vaccination ChallengesNews
The University of Bristol will contribute to a new research hub to increase global immunisation coverage and improve response to viral outbreaks through the rapid and cost-effective deployment of vaccines.READ MORE